Loading
Engineer who showed low-pass sequencing of blood can replace tumour biopsies and built ultra-sensitive MRD tests.
Viktor Adalsteinsson led the work showing that ultra-low-pass whole-genome sequencing of cell-free DNA can screen for tumour fraction and that whole-exome sequencing of plasma faithfully reproduces the tumour's mutations, enabling biopsy-free genomic profiling. His group developed MAESTRO and other methods to detect residual disease at parts-per-million sensitivity, and he directs cancer diagnostics at the Broad Institute.
| Title | Journal | Year |
|---|---|---|
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors | Nature Communications | 2017 |
| MRD detection in a variety of cancers at unprecedented sensitivity with MAESTRO (minor allele enriched sequencing through recognition oligonucleotides) | Nature Communications | 2022 |
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tag ctdna.
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tags ctdna, mrd.
Shares Nature Communications, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares MRD / molecular residual disease testing and the tag mrd.
Shares Liquid biopsy (ctDNA) and the tag diagnostics.
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tag ctdna.
Shares MRD / molecular residual disease testing and the tag mrd.
Shares MRD / molecular residual disease testing and the tag mrd.